PHYTOTHERAPEUTIC AGENTS IN THE MANAGEMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
Authors:
- Thomas H. LynchTLThomas H. Lynch
- 1 May 1995
- journal article
- review article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 22 (2) , 407-412
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Comparison of finasteride (proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibitionThe Prostate, 1993
- Evidence that Serenoa repens Extract Displays an Antiestrogenic Activity in Prostatic Tissue of Benign Prostatic Hypertrophy PatientsEuropean Urology, 1992
- Treatment of Outflow Tract Obstruction due to Benign Prostatic Hyperplasia with the Pollen Extract CerniltonBritish Journal of Urology, 1990
- In vitro Evaluation of the Pollen Extract Cernitin T‐60, in the Regulation of Prostate Cell GrowthBritish Journal of Urology, 1990
- The Value of Permixon in Benign Prostatic HypertrophyBritish Journal of Urology, 1986
- A Double-Blind Trial of the Effect of Beta-Sitosteryl Glucoside (WA184) in the Treatment of Benign Prostatic HyperplasiaEuropean Urology, 1986
- Inhibition of androgen metabolism and binding by a liposterolic extract of “serenoa repens B” in human foreskin fibroblastsJournal of Steroid Biochemistry, 1984
- A Double‐blind Trial of the Effects of Candicidin on Patients with Benign Prostatic HypertrophyBritish Journal of Urology, 1977